Actuate Therapeutics to Present at H.C. Wainwright Investment Conference

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, will present its latest advancements and corporate strategies at the H.C. Wainwright 28th Annual Global Investment Conference, taking place in New York City from September 14 to 16, 2026. The presentation, scheduled for 4:00 PM Eastern Time on Monday, September 14, 2026, will be accessible via a webcast link that will be posted on the company’s Investor section of its website.

Actuate Therapeutics focuses on developing therapies for high-impact, difficult-to-treat cancers. The company's lead investigational drug, elraglusib, is a novel GSK-3β inhibitor that targets molecular pathways in cancer, including promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy. Elraglusib works through the inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and DNA Damage Response (DDR), which are key players in the progression of cancer.

The drug also plays a role in mediating anti-tumor immunity by regulating multiple immune checkpoints and immune cell function. This comprehensive approach to cancer treatment is expected to provide significant benefits to patients suffering from difficult-to-treat cancers.

Actuate's management team will be available for one-on-one meetings during the conference, providing attendees with an opportunity to learn more about the company's research and development pipeline. This presentation is part of the company’s ongoing efforts to engage with the investment community and showcase its progress in the field of oncology.

The presentation will be available for viewing via the company's website, allowing those who cannot attend in person to follow along. Actuate Therapeutics continues to advance its mission to develop innovative cancer therapies, aiming to improve patient outcomes and provide new hope to those affected by this challenging disease.